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Abstract
Background: The development of 3, 39-diindolyl methane (DIM) resistant parasite Leishmania donovani (LdDR50) by
adaptation with increasing concentrations of the drug generates random mutations in the large and small subunits of
heterodimeric DNA topoisomerase I of Leishmania (LdTOP1LS). Mutation of large subunit of LdTOP1LS at F270L is
responsible for resistance to DIM up to 50 mM concentration.
Methodology/Principal Findings: In search of compounds that inhibit the growth of the DIM resistant parasite and inhibit
the catalytic activity of mutated topoisomerase I (F270L), we have prepared three derivatives of DIM namely DPDIM (2,29-
diphenyl 3,39-diindolyl methane), DMDIM (2,29-dimethyl 3,39-diindolyl methane) and DMODIM (5,59-dimethoxy 3,39-
diindolyl methane) from parent compound DIM. All the compounds inhibit the growth of DIM resistant parasites, induce
DNA fragmentation and stabilize topo1-DNA cleavable complex with the wild type and mutant enzyme.
Conclusion: The results suggest that the three derivatives of DIM can act as promising lead molecules for the generation of
new anti-leishmanial agents.
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Introduction
DNA topoisomerases are ubiquitous enzymes that play a pivotal
role in modulating the dynamic nature of DNA secondary and
higher order structures and carry out vital cellular processes, e.g.,
replication, repair, recombination, transcription, integration and
chromosomal segregation [1–3]. Topoisomerases are broadly
classified into two types; type I and type II. Eukaryotic
topoisomerase I is a type IB enzyme that catalyzes trans-
esterification reaction by attaching to the 39-end of the cleaved
DNA by forming phosphotyrosine linkage. All eukaryotic type IB
topoisomerases are monomeric comprising of a conserved DNA
binding domain and a COOH-terminal domain. Interestingly,
DNA topoisomerase I of kinetoplastid protozoan parasite L.
donovani is distinct from other eukaryotes with respect to its
biological properties and preferential sensitivity to many thera-
peutic agents [4,5]. L. donovani topoisomerase I (LdTOP1) consist
of two subunits, a large subunit (LdTOP1L) of 73 kDa and a small
subunit (LdTOP1S) of 29 kDa. The two proteins are synthesized
from two different genes and associate with each other through
protein-protein interaction to form an active heterodimeric
topoisomerase I within the parasite [4].
All the topoisomerase inhibitors are broadly divided into two
classes. The Class I topoisomerase inhibitors referred to as
‘‘topoisomerase poisons’’ act by stabilizing the enzyme-DNA
covalent complex (cleavable complex). A large number of
topoisomerase inhibitors were developed which play a key role
in cancer therapy. Topoisomerase II is the target of various anti-
tumor agents, like amsacrine (m-AMSA), etoposide, teniposide
and doxorubicin, which stabilize the ‘‘cleavable complex’’
between enzyme and DNA [2]. In contrast, DNA topoisomerase
I inhibitors are very rare. The most widely studied and
characterized inhibitor being camptothecin, a topoisomerase I
poison [6]. DNA topoisomerases recently have emerged as
principal therapeutic targets with a group of targeting agents
having a broad spectrum of anti-parasitic activity [7]. Because of
emergence of drug resistance in Leishmania, improved drug
therapy of Leishmania infections is still desirable and there is a
genuine need for developing therapeutic agents to combat drug
resistance.
3, 39-Diindolylmethane (DIM), a major acid condensation
product of Indole-3-Carbinol (I3C) [8], is a novel immuno
modulator that induces G1 arrest in breast cancer cells [9] and
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that DIM is a topoisomerase IIa catalytic inhibitor and it also
partially inhibits human topoisomerase I at high concentrations
[11]. Our laboratory has shown that DIM is a potent Leishmania
DNA topoisomerase 1 poison and does not stabilize topoisomerase
II-mediated cleavage [8]. DIM also induces programmed cell
death in Leishmania through inhibition of mitochondrial F0F1-ATP
synthase [12]. Adaptation of the parasite with increasing
concentrations of DIM generates random mutations in large and
small subunits of Leishmania DNA topoisomerase IB (LdTOP1LS).
A novel point mutation F270L in the large subunit has been found
to be responsible for resistance of the parasite towards the
compound [13].
In the present study, we have synthesized several derivatives
of DIM and identified three derivatives with altered phenyl,
methyl and methoxy moiety that inhibit the growth of the
resistant parasites. The compounds also inhibit the catalytic
activity of LdTOP1LS and stabilize topo1 DNA cleavable
complex. The inhibition of topoisomerase I activity by phenyl
derivative of DIM (DPDIM) is more than that of methyl
derivative (DMDIM), where as methoxy derivative (DMODIM)
causes lower inhibition. Docking studies provide a possible
explanation for the higher efficacy of DPDIM. The results
suggest that these derivatives are good candidates to be
exploited in developing rational approaches to chemotherapy
of human leishmaniasis and also can solve the prolonged DIM
resistance.
Materials and Methods
Chemicals
The bioactive DIM (3, 39-Diindolylmethane) and its derivatives
viz. DPDIM, DMDIM and DMODIM were synthesized chem-
ically from Indole and Urotropine as described [14]. The chemical
structures of the compounds are shown in Fig. 1. All drugs were
dissolved in 100% Dimethyl sulphoxide (DMSO) at 20 mM
concentration and stored at 220uC.
Cell viability assay
L. donovani strain AG83 and DIM resistant parasite DR50
promastigotes were grown at 22uC in M199 liquid media
supplemented with 10% FBS as described [12]. Axenic
amastigotes were cultured in modified M199 medium (pH 5.3)
supplemented with 10 mM sodium succinate, 40 mM HEPES
and 25% FCS and maintained at 37uCw i t h5 %C O 2.The effect
of drugs on the viability of Leishmania parasites was determined by
direct microscopic counting using light microscope (406
objective) in a haemocytometer. The cells at the exponential
phase were collected and transferred into 24-well plate (3.5610
6
cells per well). The cells were then incubated for 12 h in the
presence of various concentrations of DIM, DPDIM, DMDIM
and DMODIM (1, 5, 10, 20 and 50 mM). For other experiments,
10
4 cells were taken and grown in presence of the respective
derivatives for a period of 30 days. For each 5 day interval, a
small amount of aliquots were taken out. After incubation the
cells were centrifuged and cell pellet was washed with PBS (16)
twice and finally suspended in 1 ml PBS (16). Fifty ml of aliquot
was taken, mixed with 0.4% trypan blue solution and incubated
for 3 min at 22uC. One drop of the mixture was transferred to
haemocytometer and the clear (live) and blue (dead) cells were
counted. The total number of viable cells in aliquot was
calculated by multiplying the total number of viable cells by 2
(the dilution factor for trypan blue). To obtain the total number
of cells in the aliquot, total number of viable and nonviable cells
were added up and multiplied by 2. Percentages of viable cells
were calculated using the formula:
Live cell count7Total cell count X 100~Percentage viability
In vitro macrophage infection. Balb/c mice, originally
obtained from Jackson Laboratories, Bar Harbor, ME and reared
in the institute animal facilities, were used for experimental
purposes with prior approval of the animal ethics committee.
Macrophages were isolated from mice 36 to 48 hr post injection
(intraperitoneal) with 2% (w/v) hydrolyzed starch by peritoneal
lavage with ice-cold phosphate-buffered saline. Cells were washed
and cultured for 18–24 hr (for adherence) in RPMI 1640
(supplemented with 100 IU/ml of penicillin and 100 mg/ml of
streptomycin) containing 10% (v/v) heat-inactivated FBS (RPMI-
FBS) at 37uC with 5% CO2 in air on sterile cover glass
(22 mm622 mm) placed in disposable plates 35 mm in diameter
(Tarsons India Ltd.). The culture medium was washed off and
fresh RPMI-FBS was added. About 5610
5 macrophages
were maintained for proper distribution on cover glass. During
the course of this study, macrophages were infected with
promastigotes at a macrophage-to-parasite ratio of 1:10 in
RPMI-FBS for 6 hours to ensure entry of parasite. Following
incubation, unphagocytosed parasites were removed by washing
with medium, and cells were resuspended in RPMI-FBS at 37uC,
5% CO2 and then incubated for 6 hrs. Cultures were transferred
to a CO2 incubator at 37uC and incubated for another 10–12 hr.
Respective inhibitors were added at different concentrations
(ranging from 5 mMt o5 0mM) to infected macrophages and left
for another 24 hr period. Cells were then fixed in methanol and
stained with 2% Giemsa. Percentages of infected cells and total
number of intracellular parasites were determined by manual
counting in at least 200 cells using light microscope.
DNA fragmentation assay for detection of apoptosis
Leishmanial cells were cultured in 24-well plates and treated
with 20 mM of DIM, DPDIM, DMDIM and DMODIM for
different times. Samples were collected at requisite time points and
subjected to measurement of DNA fragmentations. Cytoplasmic
histone-associated DNA fragments (mononucleosome and oligo-
nucleosomes) formed during apoptosis were detected using a cell
death detection ELISA kit (Roche Biochemicals) by spectropho-
tometric measurement of microtiter plates in a Thermo MUL-
TISKAN EX plate reader at 405 nm. The relative percentages
(with respect to samples treated with micrococcal nuclease and
normalized to percentage values) were plotted as units of time or
drug concentrations as described previously [12].
Purification and reconstitution of recombinant LdTOP1LS
and F270L
E.coli BL21 (DE3) pLysS cells harbouring pET16bLdTOP1L,
pET16bLdTOP1L
F270L and pET16bLdTOP1S as described [8]
were separately induced at O.D600=0.6 with 0.5 mM IPTG at
22uC for 12 h. Cells were lysed and proteins were purified through
Ni
+2-NTA agarose column (Qiagen) followed by phosphocellulose
column chromatography (P11 cellulose, Whatman) as described
[8]. Finally the purified proteins LdTOP1L, LdTOP1L
F270L and
LdTOP1S were stored at 270uC. Purified LdTOP1L and
LdTOP1L
F270L were mixed with purified LdTOP1S separately
and at a molar ratio of 1:1 at a total protein concentration of
0.5 mg/ml in reconstitution buffer (50 mM potassium phosphate,
pH 7.5, 0.5 mM DTT, 1 mM EDTA, 0.1 mM PMSF, 10%
Novel Antileishmanial Derivatives of DIM
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dialyzed fractions were used for the plasmid relaxation activity.
Plasmid relaxation assay
The type I DNA topoisomerase was assayed by decreased
mobility of the relaxed isomers of supercoiled pBluescript (SK
+)
DNA in an agarose gel. Relaxation assays were carried out with
LdTOP1LS, F270LS and hTopo I in standard assay condition as
described [8]. The amount of supercoiled monomer DNA band
florescence after ethidium bromide (EtBr; 0.5 mg/ml) staining was
quantitated by integration using Gel Doc 2000 under UV
illumination (BioRad-Quality one software).
Plasmid cleavage assay
Cleavage assay was carried out as described previously [8].
Briefly, 50 fmol of pHOT1 supercoiled DNA (containing
topoisomerase I cleavage site) and 100 fmol of reconstituted
LdTOP1LS were incubated in standard reaction mixture (50 ml)
containing 50 mM Tris/HCl (pH 7.5), 100 mM KCl, 10 mM
MgCl2, 0.5 mM DTT, 0.5 mM EDTA and 30 mg/ml BSA in the
presence of various concentrations of drugs at 37uC for 30 min.
The reactions were terminated by adding 1% SDS and 150 mg/ml
proteinase K and further incubated for 1 h at 37uC. DNA samples
were electrophoresed in a 1% agarose gel containing 0.5 mg/ml
EtBr.
Equilibrium cleavage assay
The 25-mer oligonucleotide 1 (59-GAAAAAAGACTTQA-
GAAAAATTTTTA-39) was 59-end labeled with [c
32P] ATP
and annealed with oligonucleotide 2 (59-TAAAAATTTTTC-
TAAGTCTTTTTTC-39) to make a duplex oligonucleotide
containing a topoisomerase I binding motif as described [8].
Cleavage assay was carried out using 20-fold molar excess of
enzymes over duplex 25-mer DNA (enzymes, 0.2 mM; DNA,
10 nM). The reactions were carried out in standard assay
condition in the absence or presence of drugs at 37uC for
30 min. All the reactions were stopped by addition of SDS to a
final concentration of 2% (w/v), digested with 5 ml of 1 mg/ml
trypsin and analyzed by 12% denaturing polyacrylamide gel
followed by autoradiography. The amount of strand cleavage in
the presence of drugs was determined by densitometry of the film
as described [8].
Figure 1. Chemical structure of DIM and its three derivatives.
doi:10.1371/journal.pone.0028493.g001
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Leishmania cells (3610
7) were cultured in absence and presence
of the drugs. Nuclear fractions were isolated as described [8].
Briefly, cells were suspended in hypotonic buffer (10 mM Tris-
HCl, pH 7.5, 1 mM EDTA, 0.1 mM EGTA, 1 mM PMSF,
1 mM benzamidine hydrochloride and 5 mM DTT) and
homogenized. The homogenate was centrifuged for 10 min at
10,000 g. The pellets were washed and used as the source of
nuclear fraction. Thereafter, the nuclear fractions were lysed with
1% SDS and subjected to SDS-PAGE (10%). The proteins were
electrophoretically transferred to nitrocellulose membranes and
immumobloting of immobilized proteins were carried out using a
rabbit polyclonal antibody raised against LdTOP1S for topoisom-
erase I and ATPase domain of L. donovani topoisomerase II [8].
Spectrofluorometric binding assay
Fluorescence titration was measured using Perkin Elmer, LS55,
and Luminescence spectrometer. The intrinsic binding of DIM-
derivatives to DNA was performed separately by fluorescence
measurements at an excitation wavelength of 335 nm, 265 nm
and 338 nm and emission range of 350 to 450 nm, 300 to 450 nm
and 380 to 540 nm for DPDIM, DMDIM and DMODIM,
respectively. Excitation and emission slit widths were 5 nm and
7.5 nm; 5 nm and 15 nm; and 5 nm and 15 nm for DPDIM,
DMDIM and DMODIM, respectively. Background emission
(,2%) was corrected by subtraction of spectra of blank buffer,
DNA plus sample buffer and compounds plus sample buffer,
respectively. Spectral titration was performed with DIM deriva-
tives at 25uC in fluorescence buffer (20 mM Tris-HCL, pH 7.5,
50 mM NaCl and 10 mM MgCl2). CT DNA was added in
increasing concentrations (10 to 200 mM), which are indicated in
the legend. All the assays were performed in duplicate, titration
points are corrected as described above and binding constants for
DIM DNA-compound interaction were determined according to
following equation:
1=DF~1=DFmaxz(1=Ka:St)(1=DFmax) ðEq   1Þ
where DF=F x2Fo,F x and Fo representing the florescence
intensity of DIM derivatives in the presence or absence of the
added total DNA (St), respectively. DFmax is the maximum change
in the fluorescence intensity. The intercept of the plot on the 1/F
axis corresponding to 1/St=0 measures the 1/Fmax, while the
slope gives the estimation of the affinity constant (Ka). The
dissociation constant KD=1/Ka.
Molecular Docking procedure
Docking experiments have been carried out, for each DIM
derivative, using as receptor the crystal structure of the
LdTOP1LS complex taken from the PDB structure 2B9S [15]
where residues 27–456 and 221–262 of the large and small
subunits respectively are present. Residues missing in the crystal
structure, 427–430 of the large subunit have been modeled with
the program Swiss-PdbViewer v. 4.0.1 [16]. The GROMOS force
field implemented in the program has been used to regularize the
structure in order to avoid clashes. Further the program has been
used to substitute the 22 DNA double strand present in the crystal
structure, with the 22 DNA double strand present in the human
Top1-DNA-topotecan ternary complex, coming from the PDB
structure 1K4T [17], by fitting the two molecules on the backbone
atoms. The substitution has been done since the presence of a
cleaved site in the 22 double strand present in the 1K4T X-ray
structure that contains the topotecan molecule permits to
investigate the ability of the three compounds to interact with
the LdTOP1LS-DNA cleavable complex. 250 docking runs for
each compound have been carried out with the Autodock 4
program, using the AutodockTools suite v. 4 to prepare the
structures of the ligands and the receptor [18] and making use of
the Lamarckian Genetic Algorithm [19] to generate the docked
complexes. The dimensions of the cubic simulative box that
contains the protein-DNA complex are 48648648 A ˚ 3. Images
have been obtained with the VMD visualization package [20].
Results
Derivatives of DIM exert cytotoxic effect on wild type and
DIM resistant L. donovani promastigotes
The effects of different derivatives of DIM on cell proliferation
were tested by incubating wild type and DIM resistant L. donovani
promastigotes (3.5610
6 cells/ml) with the drugs. The resistant
parasites were developed by progressive adaptation as mentioned
in Materials & Methods with five different concentrations of DIM,
DPDIM, DMDIM and DMODIM (1, 2, 5, 10, 20 and 50 mM) for
12 h. The number of live promastigotes was measured by
differential staining of live and dead cells using light microscope
under 406 objective (Fig. 2). The results indicated that the
derivatives exhibited concentration dependent growth inhibitory
effects on Leishmania parasites. At 12 h, 88%, 96% and 83%
growth were inhibited by 20 mM of DIM, DPDIM and DMDIM
respectively, whereas 70% growth was inhibited by 20 mMo f
DMODIM (Fig. 2A). In case of DIM resistant parasites 20%,
90%, 85% and 65% growth were inhibited by 20 mM DIM,
DPDIM, DMDIM and DMODM respectively (Fig. 2B). The
above results suggest that all the three derivatives are cytotoxic to
wild type and DIM resistant L. donovani AG83 promastigotes.
When DIM resistant DR
50 cells were grown continuously in
presence of DIM, the parasites survived in presence of DIM and
multiply in culture. But incubation with the three derivatives
separately shows that the numbers of viable parasites were
decreased as the incubation time is increased. DPDIM shows an
IC50 of 2.3 mM at 24 hour incubation but after 10 days the IC50
value is decreased almost three times after 10 day incubation
period. Further incubation up to 20 days steeply decreases the
number of viable parasites and a 30 day incubation period shows
an IC50 value of only 50 nM (Fig. 2C). So prolonged exposure of
DIM derivatives (DPDIM) does not confer resistance to DIM
resistant (DR
50) promastigotes. This result is also comparable with
DMDIM. After a 30 day long exposure the IC50 values have been
changed 10 times. DMODIM has the high IC50 value at 24 h
(7.26 mM) and has a steepest change in IC50 value over the 30 day
exposure.
Figure 2. Effect of DIM-derivatives on Leishmania parasites. Growth of L. donovani AG83 promastigotes (A) and DIM resistant promastigotes
(B) were monitored in presence of increasing concentrations (1, 5, 10, 20 and 50 mM) of DIM, DPDIM, DMDIM and DMODIM for 12 h. Proliferation of
Leishmania strain in absence of treatment was considered as a maximal growth control. Change in IC50 values after a prolong exposure to DIM
derivatives (C) has been assessed as described in Materials and Methods. After every 5 day a small aliquot was taken out and number of viable
promastigotes was counted for each concentration. IC50 values have been determined from them using Graph Pad Prsim ver 5.0 software and a
graphical plot was generated over time. Growth of the parasites treated with the compounds was expressed as percentage of the viable
promastigotes compared with that of control. The results (percentage over control 6 SD) were representative of three experiments.
doi:10.1371/journal.pone.0028493.g002
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infected cultured macrophages and kills DIM resistant
axenic amastigotes
Primary macrophage cells were obtained from Balb/c mice
peritoneal extrudates. After adherence and inactivation, these
macrophage cells were infected with early passaged L. donovani
AG83 promastigotes were infected to macrophages. After
subsequent washing they were incubated with different concen-
trations (5, 10, 20 and 50 mM) of each of these inhibitors for 24 h
(Fig. 3A). Macrophages were fixed and intracellular amastigotes
were counted by Giemsa staining. In case of DIM, DPDIM and
DMDIM the efficiency of amastigote killing is upto 91%, 96% and
92% when treated with 50 mM of the drugs respectively.
DMODIM is less potent in reducing the number of parasites like
other three compounds. DMODIM clears about 85% of
Leishmania parasites from macrophages.
Figure 3. Effectiveness of clearance of internalized L. donovani (AG83) from in vitro infected mouse Mw
&
. (A) Macrophages from
peritoneal extrudate of Balb/c mouse were infected with parasites. Cultures were treated with DIM, DPDIM, DMDIM and DMODIM separately as
indicated in Materials and Methods. Incubations were carried out for 24 hours. Cells were fixed, stained with Giemsa and counted under bright field
microscope. Dose dependent amastigote clearance by DIM and its derivatives from infected macrophages were plotted. Experiments were carried
out for three times and representative results are the mean 6 S.D. (B) Growth of DIM resistant L. donovani axenic amastigotes were monitored in
presence of increasing concentrations (2, 5, 10, 20 and 50 mM) of DIM, DPDIM, DMDIM and DMODIM for 12 h. Proliferation of Leishmania strain in
absence of treatment was considered as a maximal growth control. Growth of the parasites treated with the compounds was expressed as
percentage of the viable promastigotes compared with that of control. The results (percentage over control 6 SD) were representative of three
experiments.
doi:10.1371/journal.pone.0028493.g003
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amatigotes. The transformation of promastigotes to axenic
amastigotes was confirmed by observing under light microscopy.
The effects of different derivatives of DIM on cell proliferation
were tested by incubating DIM resistant L. donovani amastigotes
(2610
4 cells/ml) with DIM, DPDIM, DMDIM and DMODIM
separately (2, 5, 10, 20 and 50 mM) for 12 h. The number of live
amastigotes was measured by differential staining of live and dead
cells using light microscope under 406 objective (Fig. 3B). The
results indicated that the derivatives exhibited concentration
dependent growth inhibitory effects on Leishmania parasites. At
12 h, 98%, 92% and 79% growth were inhibited by 50 mMo f
DPDIM, DMDIM and DMODIM respectively (Fig. 3B).
The derivatives of DIM induce fragmentation of genomic
DNA in wild type and DIM resistant Leishmania parasites
The internucleosomal DNA digestion by an endogenous
nuclease (genomic DNA fragmentation) is considered as a
hallmark of apoptotic cell death [21]. Previously, we found that
DIM induces genomic DNA fragmentation in Leishmania parasites
[12]. To investigate whether these derivatives also do the same, we
performed the DNA fragmentation assay with wild type L. donovani
AG83 promastigotes and DIM resistant parasites (Fig. 4) by
ELISA as described in Materials and Methods. Results show that
there were 73%, 79%, 60% and 49% fragmentation of DNA in
wild type promastigotes at 6 h by treatment with 20 mM of DIM,
DPDIM, DMDIM and DMODIM respectively. DNA fragmen-
tation increased to 85%, 89%, 81% and 71% at 8 h of treatment
in wild type parasites. The DIM resistant parasites (LdDR50) have
much less effect in DNA fragmentation (13% at 6 h and 17% at
8 h) when treated with 20 mM DIM. On the other hand the
extents of DNA fragmentations were 63%, 51% and 40% at 6 h
treatment with DPDIM, DMDIM and DMODIM respectively.
The extent of fragmentation increased to 82%, 74% and 65%
after treatment for 8 h with the drugs as mentioned above. The
above results suggest that DNA fragmentation may be responsible
for drug induced cell death.
DIM-derivatives stabilize topo I-DNA cleavable
complexes formation in vitro
The effect ofDIMand itsderivatives onL. donovani topoisomerase
I was examined by plasmid DNA cleavage assay as described [8].
The topoisomerase reaction has three general mechanistic steps: (i)
binding of enzyme to the substrate DNA, (ii) single strand breakage
and subsequent strand rotation through the break leading to change
in linking number, and (iii) strand religation. The second step of
reaction is the introduction of a single-stranded nick in the
phosphodiester bond of the DNA, through which an intact strand
is allowed to pass. During this process, a covalent bond is formed
between the 39-phosphoryl group of the DNA backbone and the
tyrosine residue at the active site of topoisomerase I. Topoisomerase
inhibition can be achieved by prevention of enzyme-DNA binary
complex formation or by stabilization of enzyme-DNA cleavable
complex. To investigate the ability of DIM-derivatives to stabilize
the cleavable complex formation between enzyme and oligonucle-
otide containing a topoisomerase IB specific binding motif we
carried out plasmid cleavage assay as described previously [8].
Cleavage assay was performed with LdTOP1LS and pHOT1 DNA
containing a topoisomerase IB specific binding motif as described in
‘Materials and Methods’. As shown in Fig. 5A, in presence of
50 mM CPT, the closed circular DNA (form I) was totally converted
to nicked circular DNA (form II, lane 4). The result was same with
20 mM DIM (lane 6), 10 mM DPDIM (lane 7) and 20 mM DMDIM
(lane 10). However, treatment with 20 mM DMODIM didn’t cause
conversion of all the form I DNA to form II (lane 12). The above
observation was further supported by duplex oligonucleotide
cleavage assay as described [8]. The experiment was performed
by incubating duplex oligonucleotide with topoisomerase I in
presence of 5, 10, 15 and 20 mM of DPDIM, DMDIM and
DMODIM. In the absence of drugs, the cleavage-religation
Figure 4. DIM derivatives-induced fragmentation of genomic DNA in wild type and DIM resistant parasites. Relative percentage of
DNA fragmentation measured by cell death detection ELISA kit in L. donovani promastigotes treated with DIM, DPDIM, DMDIM and DMODIM. The
experiments were performed three times and representative data from one of these experiments as means 6 SD.
doi:10.1371/journal.pone.0028493.g004
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28493Figure 5. DIM-derivatives stabilize LdTOP1LS-mediated DNA cleavage. (A) Plasmid Cleavage experiment. Cleavage reaction and agarose
gel electrophoresis were performed as described in ‘Materials and Methods’. Lane 1, 50 fmol of pHOT1 DNA; lane 2, with 100 fmol LdTOP1LS; lanes 3
and 4, same as lane 2, but in the presence of 25 and 50 mM CPT respectively as control; lanes 5 and 6, same as lane 2, but in the presence of 10 and
20 mM DIM respectively; lanes 7 and 8, same as lane 2, but in the presence of 10 and 20 mM DPDIM respectively; lanes 9 and 10, same as lane 2, but in
the presence of 10 and 20 mM DMDIM respectively; lanes 11 and 12, same as lane 2, but in the presence of 10 and 20 mM DMODIM respectively.
Novel Antileishmanial Derivatives of DIM
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(LdTOP1LS), as little trapped cleavable complex was found and
most of the cleaved product is religated and migrated as uncleaved
25-mer (panels C, D and E, lane 2). When the wild type enzyme is
exposed to increasing concentration of DPDIM the cleavage-
religation equilibrium is shifted towards cleavage. The band
corresponding to the 12-mer cleaved products is clearly detectable
and the band intensity is increased with increasing concentration of
DPDIM (panel C, lanes 3–6). We have previously found that the
F270L topoisomerase I mutant is insensitive to DIM [13].
Therefore, we have investigated whether the three DIM derivatives
could interact with the DIM-resistant F270L mutant stabilizing the
topoisomerase I-DNA cleavable complex. In the presence of
increasing concentrations of three DIM-derivatives the equilibrium
is shifted towards cleavage as revealed by the appearance of 12-mer
cleaved product on the gel for both wild type (Fig. 5C, D and E;
lanes 3–6) and F270L mutant enzyme (Fig. 5C, D and E; lanes 8–
12). Moreover, all the three derivatives enhanced cleavage with
increasing concentrations of the drugs. DPDIM-induced cleavage
increased to 67% in presence of wild type enzyme (Fig. 5C, lane 6)
and 56% in presence of F270L mutant (lane 12) at 20 mM
concentration with respect to the extent of cleavable complex
formedwithoutthedrug inpresence ofwild type enzyme. At 20 mM
DMDIM and DMODIM, the extent of cleavage reached
approximately 61% and 56% respectively in presence of wild type
enzyme (Fig. 5D and E, lane 6), and 53% and 50% in presence of
F270L mutant respectively (Fig. 5D and E, lane 12). These results
indicate that the three derivatives are potent topoisomerase I
poisons. Moreover, although F270L is insensitive to DIM [13] and
all three DIM-derivatives stabilize the cleavable complexes in
F270L mutant enzyme, the binding site of DIM might not be
overlapping and may be different from the derivatives.
DIM-derivatives stabilize in vivo cleavable complex
formation in L. donovani promastigotes
We have reported earlier that DIM induces topoisomerase I and
not topoisomerase II-mediated cleavable complex formation in L.
donovani [8]. To investigate the ability of DIM derivatives to induce
in vivo covalent complex formation between topoisomerase I and
DNA in the Leishmania parasites we performed the immunoband
depletion experiments with L. donovani promastigotes. Nuclear
fractions were prepared from untreated as well as drug-treated
promastigotes and subjected to SDS-PAGE. If topoisomerase I can
form a covalent complex with genomic DNA inside the cells, then
topoisomerase I-DNA cleavable complex cannot enter into the gel.
On the other hand, if topoisomerase I does not form a complex
with DNA and remains free, it will enter into the gel. The presence
of topoisomerase I was detected by immunoblotting as described
in ‘Materials and Methods’. The immunoband depletion data are
summarized in Figure 6. It was observed that the immunoband of
topoisomerase I disappeared in presence of 20 mM of DIM,
DPDIM, DMDIM and DMODIM for 6 h incubation respectively
(lanes 2–5). Preincubation with 20 mM DHBA before treatment
with drugs causes reappearance of immunoband of L. donovani
topoisomerase I as cleavable complex formation is prevented
(lanes 6–9). The above results suggest that DIM is responsible for
the stabilization of topoisomerase I-DNA cleavable complex inside
the cells. It should be mentioned here that topoisomerase I of
Leishmania is a heterodimer and the catalytic site (SKXXY) is
present in the small subunit of enzyme (LdTOP1S), which is
involved in the formation of topoisomerase I-DNA covalent
complex. So we have used the antibody raised against the small
subunit of L. donovani topoisomerase I to study the immunoband
depletion assay.
To rule out the topoisomerase II mediated cleavable complex
stabilization by the derivatives, we have carried out immunoband
depletion assay with antibody raised against ATPase domain
(43 kDa) of L. donovani topoisomerase II. The results (Figure S1)
clearly indicate that DIM and its derivatives do not stabilize
cleavage complex formation mediated by Leishmania topoisomerase
II.
Interaction of derivatives of DIM with DNA as studied by
fluorescence quenching
DIM interacts with DNA with the dissociation constant (KD)o f
2.2610
25 M [8]. Therefore, it was of interest to determine
whether DIM derivatives could interact with DNA. Fluorescence
quenching assay was performed to determine the interaction
between the derivatives of DIM and DNA at different concentra-
tions of DNA (10 to 200 mM). DPDIM has fluorescence emission
maximum (lem
max) at the wavelength of 390 nm with a lex of
335 nm, whereas DMDIM has fluorescence emission maximum at
a wavelength of 379 nm with a lex of 265 nm and DMODIM has
fluorescence emission maximum at a wavelength of 450 nm with a
lex of 338 nm. The excitation and emission slit widths were set at
Positions of supercoiled monomer (SM; form I) and nicked monomer (NM; form II) are indicated. (B) Oligo sequence used for the Equilibrium cleavage
assay. An arrow indicates the cleavage site. (C), (D) and (E) Duplex oligonucleotide cleavage. The cleavage reactions and electrophoresis in a
denaturating polyacrylamide gel were performed as described in Materials and Methods. (C) Lane 1, 10 nM of 59-
32P-end labeled 25 mer duplex
oligonucleotides as indicated above. Lane 2, same as lane 1, but incubated with 0.2 mM of wild type enzyme. Lanes 3 to 6, same as lane 2, but
incubated with 5, 10, 15 and 20 mM of DPDIM respectively for 60 min at 23uC. Lane 7, same as lane 1; lanes 8, same as lane 7, but incubated with
0.2 mM of F270L mutant enzyme. Lanes 9–12, same as lane 8, but incubated with 5, 10, 15 and 20 mM of DPDIM respectively for 60 min at 23uC. (D
and E) Same as (C), but incubated with 5, 10, 15 and 20 mM of DMDIM and DMODIM respectively. All the reactions were stopped by addition of SDS
to the final concentration of 2% (w/v). Samples were precipitated with ethanol, digested with trypsin and analyzed by 12% denaturing
polyacrylamide gel as described in Materials and Methods.
doi:10.1371/journal.pone.0028493.g005
Figure 6. DIM-derivatives induce in vivo formation of topo-
isomerase-DNA cleavable complex within the cells. Stabilization
of topoisomerase-I mediated cleavable complex was determined by
immunoband depletion assay. Top panel: Immunoband depletion of L.
donovani topoisomerase I, using an antibody raised against LdTOP1LS.
Leishmanial cells were treated with 0.2% DMSO alone (lane 1), 20 mM
each of DIM (lane 2), DPDIM (lane 3), DMDIM (lane 4) and DMODIM (lane
5) respectively. Lanes 6–9, preincubation with 20 mM DHBA before
treatment with DIM, DPDIM, DMDIM and DMODIM respectively. Bottom
panel: b-tubulin loading control.
doi:10.1371/journal.pone.0028493.g006
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and 5 nm and 15 nm for DMODIM. Appropriate blanks
corresponding to the buffer were subtracted to correct the
background fluorescence. The fluorescence intensity decreases by
increasing the concentration of DNA due to quenching reaction.
Addition of DNA causes a slight shift of the maximum peak (l
shift) from 390 nm to 386 nm for DPDIM and from 379 nm to
374 nm for DMDIM with a concomitant decrease in fluorescence
intensity (Fig. 7A and B). There is no l shift for DMODIM
(Fig. 7C). A progressive change in the fluorescence spectra of three
DIM-derivatives on addition of different concentrations of DNA
indicated an association between them. The dissociation constant
(KD) calculated using Scatchard analysis [22] was 1.1610
25 M for
DPDIM, 6.3610
25 M for DMDIM and 4.8610
25 M for
DMODIM. The above results indicate that the affinity of DPDIM
to DNA is 2-fold greater compared to the DIM mother compound
[8] and the affinity of DMDIM and DMODIM to DNA are
approximately 3-fold and 2-fold less compared to DIM, respec-
tively.
Docking of DMDIM, DMODIM and DPDIM on the
protein-DNA cleavable complex
It is shown earlier that in the presence of these derivatives, the
cleavage-religation equilibrium is shifted towards cleavage. The
ability of DIM derivatives to impair the religation reaction of
LdTOP1LS has been investigated through Molecular Docking, to
define the interaction mode between the drugs and the protein-
DNA covalent complex, as recently done to predict the inhibition
mode of Erybraedin C on human topoisomerase IB [23]. Figure 8
shows the spread of the 250 docked structures for the three
compounds.
DMDIM and DMODIM (Fig. 8A and B) show a similar
interaction profile, in fact in both cases the docked molecule is
spread out along all the DNA structure, between base pairs 5–19.
All the molecules have a comparable interaction energy ranging
between 26 and 210 Kcal/mol indicating that the two molecules
do not have a preferential binding site and only some of them
docks in proximity of the active site. On the other hand DPDIM
docks in a unique binding region (Fig. 8C), in fact in all 250 runs
the molecule is located in a single site. In detail, all the docked
molecules are found in the DNA minor groove and the free energy
of the complexes are also characterized by a very narrow range
between 28.1 and 29.8 Kcal/mol. The drug binding site is
localized between base pairs 10–14, relatively close to the active
site, and its inhibitory effect on the religation reaction, could be
explained either through an impairing of the process of strand
rotation or to a direct slowing of the religation process.
Discussion
Emergence of resistance against conventional drugs for
leishmaniasis poses great problem in the treatment and therefore
genuinely demands development of new therapeutics. DIM has
been shown to have several pharmacological properties [8]. Our
laboratory has shown that this phytochemical is a potent Leishmania
topoisomerase I poison [8]. Therefore in order to study the
mechanism of resistance and to circumvent the problem of
resistance, we have developed DIM resistant L. donovani parasites
by progressive adaptation to the drug [13] and synthesized several
derivatives of DIM.
In the previous study, we have identified that DIM is a potent
inhibitor of LdTOP1LS and also kills the parasites via induction of
apoptosis by abrogating Fo-F1 ATP synthase function. Develop-
ment of resistance to DIM is due to mutation in LdTOP1LS
(F270L) and also due to overcoming Fo-F1 ATP synthase
inhibition. Development of DIM derivatives as antileishmanial
drugs emphasizes on the selective inhibition of DIM resistant
parasites. Therefore to develop resistance against one of the DIM
derivatives it is necessary to acquire gene mutation in LdTOP1LS
(F270L) as well as in Fo-F1 ATP synthase. Docking experiments
suggested a possible binding site of the three derivatives. In detail,
DPDIM displays a higher specificity for binding than the other
two compounds. It interacts with the cleavable complex at the
level of the DNA minor groove. Finally it inhibits further religation
Figure 7. Fluorescence quenching study of DIM derivatives-DNA interaction. (A) CT DNA concentration-dependently quenched DPDIM
fluorescence at 390 nm. (B) CT DNA concentration-dependently quenched DMDIM fluorescence at 379 nm. (C) CT DNA concentration-dependently
quenched DMODIM fluorescence at 450 nm. The arrow of each figure indicates the change in the emission spectra of DPDIM, DMDIM and DMODIM
respectively on addition of CT DNA.
doi:10.1371/journal.pone.0028493.g007
Figure 8. Docking results. Spread of the 250 DMDIM (A), DMODIM
(B) and DPDIM (C) molecules docked on the heterodimeric LdTOP1LS-
DNA complex. The protein is represented in ribbons, with the large
subunit colored in red and the small subunit colored in green. The DIM
derivatives are represented in licorice with the C, O and H atoms
colored cyan, red and white respectively.
doi:10.1371/journal.pone.0028493.g008
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markedly different with that of DIM-LdTOP1LS binding. The
binding causes the three derivatives to stabilize the topoisomerase
I-DNA cleavable complexes in vitro with the wild type and F270L
mutant enzyme (Fig. 5). In vivo cleavable complex stabilization also
substantiate with the in vitro observations. Therefore it might be
concluded from the catalytic inhibition of wild type enzyme by the
three derivatives and the topo I- DNA cleavable complex
formation between the mutant enzyme and the three derivatives
that the binding site of DIM to enzyme is not overlapping with the
derivatives.
Previously we have shown that DIM resistant parasites inherit
the F270L mutation and no known drug transporters were
associated with the resistance phenotypes [13]. This implies that
DIM stays well within the parasites and progressive adaptation is
selected by constant drug pressure. Real time PCR analysis
showed that in DIM resistant parasites the levels of large and small
subunits of LdTOP1LS were decreased. So there is no possibility
to tie up the inhibitor by the enzyme to prevent its action. By
adaption to DIM derivatives the DIM resistant parasites need to
accumulate more mutation to become resistant to these deriva-
tives. Some simple substitutions to DIM confer the DIM resistant
parasites to become sensitive to these derivatives. Fluorescence
quenching experiments revealed that DPDIM has 2-fold higher
affinity to DNA than DIM. However, DMDIM and DMODIM
have 3-fold and 2-fold lower affinity to DNA than DIM
respectively. Again a long term exposure of these derivatives to
DR50 cells shows that IC50 values were decreased as incubation
time is increased. When DIM is applied to DIM resistant parasites,
the number of viable parasites increases with time over a period of
30 days. But when DIM resistant parasites were treated with the
derivatives, the number of viable parasites decreased with time.
This experiment proves that resistance is not acquired in DR50
parasites upon prolong incubation of these derivatives. DPDIM
being the strongest drug shows a loweset IC50 value and change in
IC50 values over 30 days is lowest amongst the three derivatives.
DPDIM kills almost all DR50 cells in 30 days incubation period
supporting that development of further resistance is low if DPDIM
is used for treatment.
In conclusion, the present study indicates that among all the
compounds, DPDIM is the most potent antileishmanial agent and
all the three derivatives are potent Leishmania topoisomerase I
poison. Structure-function analysis of enzyme-drug interactions
along with modeling studies might be exploited in developing
rational approaches to chemotherapy of human leishmaniasis and
can also facilitate the study of future DIM resistance.
Supporting Information
Figure S1 Stabilization of topoisomerase-II mediated
cleavable complex was determined by immunoband
depletion assay. Immunoband depletion of L. donovani topo-
isomerase II, using an antibody raised against LdTOP2 (ATPase
domain, 43 kDa). Leishmanial cells were treated with 0.2% DMSO
alone (lane 1), 20 mM CPT (lane 2); 20 mM and 50 mMo f
Etoposide (lanes 3 and 4 respectively) and 50 mM of DIM (lane 5),
DPDIM (lane 6), DMDIM (lane 7) and DMODIM (lane 8)
respectively.
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